Your browser is no longer supported. Please, upgrade your browser.
Imago BioSciences, Inc.
Index- P/E- EPS (ttm)-4.41 Insider Own1.40% Shs Outstand30.80M Perf Week-4.71%
Market Cap574.26M Forward P/E- EPS next Y-1.81 Insider Trans-5.59% Shs Float16.21M Perf Month-32.89%
Income- PEG- EPS next Q-0.39 Inst Own72.20% Short Float10.94% Perf Quarter-37.73%
Sales- P/S- EPS this Y-63.60% Inst Trans0.39% Short Ratio8.00 Perf Half Y0.59%
Book/sh7.41 P/B2.29 EPS next Y56.30% ROA- Target Price35.33 Perf Year-
Cash/sh6.82 P/C2.49 EPS next 5Y- ROE- 52W Range14.61 - 35.68 Perf YTD-28.30%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-49.55% Beta-
Dividend %- Quick Ratio26.30 Sales past 5Y- Gross Margin- 52W Low23.20% ATR2.02
Employees20 Current Ratio26.30 Sales Q/Q- Oper. Margin- RSI (14)42.02 Volatility7.45% 9.98%
OptionableNo Debt/Eq0.00 EPS Q/Q-174.90% Profit Margin- Rel Volume3.18 Prev Close17.00
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume221.76K Price18.00
Recom1.20 SMA20-8.64% SMA50-13.83% SMA200-18.08% Volume294,684 Change5.88%
Jan-19-22 08:00AM  
Jan-14-22 06:28AM  
Dec-17-21 08:00AM  
Dec-12-21 09:46AM  
Dec-11-21 12:01PM  
Dec-01-21 08:00AM  
Nov-18-21 04:05PM  
Nov-11-21 04:05PM  
Nov-10-21 04:05PM  
Nov-04-21 04:05PM  
Oct-16-21 10:45AM  
Sep-20-21 08:00AM  
Aug-19-21 04:01PM  
Jul-30-21 08:02AM  
Jul-26-21 04:15PM  
Jul-20-21 05:15PM  
Jul-15-21 10:34PM  
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Peppe JenniferSee RemarksJan 12Option Exercise1.7914,00025,059162,809Jan 14 06:48 PM
Tapper Amy E.See RemarksJan 12Option Exercise1.526,0009,120125,047Jan 14 06:47 PM
Eichorn Laura G.See RemarksJan 12Option Exercise1.528,00012,160215,737Jan 14 06:46 PM
Tapper Amy E.See RemarksJan 12Sale19.966,000119,750119,047Jan 14 06:47 PM
Peppe JenniferSee RemarksJan 12Sale19.9514,000279,353148,809Jan 14 06:48 PM
Eichorn Laura G.See RemarksJan 12Sale19.968,000159,651207,737Jan 14 06:46 PM